Express News | Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024

ReutersJul 17 16:15 ET

Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings Trajectory Could Turn Positive as the Stock Climbs 5.5% This Past Week

As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. We regret

Simply Wall StJul 17 14:38 ET

How Is The Market Feeling About Jazz Pharmaceuticals?

Jazz Pharmaceuticals's (NYSE:JAZZ) short percent of float has risen 4.88% since its last report. The company recently reported that it has 2.68 million shares sold short, which is 5.59% of all

BenzingaJul 15 15:00 ET

Morgan Stanley Maintains Jazz Pharmaceuticals(JAZZ.US) With Hold Rating, Cuts Target Price to $150

Morgan Stanley analyst Jeffrey Hung maintains $Jazz Pharmaceuticals(JAZZ.US)$ with a hold rating, and adjusts the target price from $160 to $150.According to TipRanks data, the analyst has a success

Moomoo NewsJul 12 08:31 ET · Ratings

Jazz Pharmaceuticals (JAZZ) Receives a Hold From Morgan Stanley

TipRanksJul 12 08:26 ET

Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US

The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical

BenzingaJul 11 15:01 ET